AdAlta’s Shark Antibody, Potential Way of Treating Lung Fibrosis, Nearing 1st Clinical Trial
A lung fibrosis treatment based on a shark antibody is on the verge of entering a first clinical trial in patients. The treatment has shown promise in animal models of fibrosis, and offers hope for a therapy that is superior to current treatment approaches for lung fibrosis. Developed by Australian-based AdAlta, the compound is a…